PA8472601A1 - Agonistas y antagonistas il-2 selectivos - Google Patents
Agonistas y antagonistas il-2 selectivosInfo
- Publication number
- PA8472601A1 PA8472601A1 PA19998472601A PA8472601A PA8472601A1 PA 8472601 A1 PA8472601 A1 PA 8472601A1 PA 19998472601 A PA19998472601 A PA 19998472601A PA 8472601 A PA8472601 A PA 8472601A PA 8472601 A1 PA8472601 A1 PA 8472601A1
- Authority
- PA
- Panama
- Prior art keywords
- cells
- muteine
- human
- agonists
- antagonists
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/55—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Virology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
LA PRESENTE INVENCION ESTA ORIENTADA A UN POLIPEPTIDO QUE COMPRENDE UNA MUTEINA DE IL-2 HUMANA NUMERADA DE ACUERDO CON LA IL-2 DE TIPO SALVAJE EN LA CUAL DICHA IL-2 HUMANA ESTA SUSTITUIDA EN POR LO MENOS UNA DE LAS POSICIONES 20, 88 O 126, CON LO CUAL DICHA MUTEINA ACTIVA CELULAS T CON MAYOR PREFERENCIA CON RESPECTO A LAS CELULAS NK. EL D20H E I, N88G, I, Y R, EN PARTICULAR, TIENEN UNA ACTIVIDAD DIFERENCIAL PARA LA CELULAS T, MUCHO MAYOR QUE LA IL-2 NATIVA, CON UNA TOXICIDAD IN VIVO ASOCIADA PREDICHA, REDUCIDA. LA INVENCION TAMBIEN PROVEE POLINUCLEOTIDOS QUE CODIFICAN LAS MUTEINAS DE LA INVENCION, VECTORES QUE CONTIENEN LOS POLINUCLEOTIDOS, CELULAS HOSPEDANTES TRANSFORMADAS, COMPOSICIONES FARMACEUTICAS QUE CONTIENEN LAS MUTEINAS, Y METODOS TERAPEUTICOS DE TRATAMIENTO.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US8008098A | 1998-05-15 | 1998-05-15 |
Publications (1)
Publication Number | Publication Date |
---|---|
PA8472601A1 true PA8472601A1 (es) | 2000-09-29 |
Family
ID=22155135
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PA19998472601A PA8472601A1 (es) | 1998-05-15 | 1999-05-13 | Agonistas y antagonistas il-2 selectivos |
Country Status (39)
Country | Link |
---|---|
EP (1) | EP1076704B1 (es) |
JP (1) | JP4276783B2 (es) |
KR (1) | KR100607609B1 (es) |
CN (2) | CN100366742C (es) |
AR (1) | AR020322A1 (es) |
AT (1) | ATE351907T1 (es) |
AU (1) | AU759697B2 (es) |
BG (1) | BG65139B1 (es) |
BR (1) | BRPI9910504B1 (es) |
CA (1) | CA2327349C (es) |
CO (1) | CO5070701A1 (es) |
CU (2) | CU23273B7 (es) |
CY (1) | CY1107533T1 (es) |
CZ (1) | CZ302071B6 (es) |
DE (1) | DE69934881T2 (es) |
DK (1) | DK1076704T3 (es) |
DZ (1) | DZ2788A1 (es) |
ES (1) | ES2281175T3 (es) |
HK (1) | HK1039963B (es) |
HN (1) | HN1999000075A (es) |
HU (1) | HU226142B1 (es) |
IL (2) | IL139136A0 (es) |
MY (1) | MY130274A (es) |
NO (1) | NO329235B1 (es) |
NZ (1) | NZ508098A (es) |
PA (1) | PA8472601A1 (es) |
PE (1) | PE20000475A1 (es) |
PL (1) | PL201675B1 (es) |
PT (1) | PT1076704E (es) |
RO (1) | RO122150B1 (es) |
RU (1) | RU2235729C2 (es) |
SI (1) | SI20643B (es) |
SK (1) | SK288100B6 (es) |
SV (1) | SV1999000061A (es) |
TN (1) | TNSN99090A1 (es) |
TR (1) | TR200003354T2 (es) |
TW (1) | TWI223663B (es) |
UA (1) | UA73719C2 (es) |
WO (1) | WO1999060128A1 (es) |
Families Citing this family (77)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6566500B1 (en) | 1999-03-30 | 2003-05-20 | Board Of Regents, The University Of Texas System | Compositions and methods for modifying toxic effects of proteinaceous compounds |
EP1935431A3 (en) | 2000-05-15 | 2008-08-13 | Health Research, Inc. | Cancer treatments by using a combination of an antibody against her2 and interleukin-2 |
US6689353B1 (en) * | 2000-06-28 | 2004-02-10 | Bayer Pharmaceuticals Corporation | Stabilized interleukin 2 |
US7723102B2 (en) * | 2000-09-28 | 2010-05-25 | Bayer Corporation | Enhanced transfection system |
MY139948A (en) * | 2000-09-28 | 2009-11-30 | Bayer Corp | Enhanced transfection system |
US6992174B2 (en) | 2001-03-30 | 2006-01-31 | Emd Lexigen Research Center Corp. | Reducing the immunogenicity of fusion proteins |
MXPA04005266A (es) * | 2001-12-04 | 2004-10-11 | Merck Patent Gmbh | Inmunocitocinas con selectividad modulada. |
WO2005007121A2 (en) | 2003-07-18 | 2005-01-27 | Massachusetts Institute Of Technology | Mutant interleukin-2(il-2) polypeptides |
DE602004031341D1 (de) | 2003-07-21 | 2011-03-24 | Transgene Sa | Multifunktionelle cytokine |
WO2005014642A2 (en) | 2003-07-21 | 2005-02-17 | Transgene S.A. | Novel multifunctional cytokines |
PT1682178E (pt) | 2003-11-04 | 2010-10-21 | Novartis Vaccines & Diagnostic | Métodos de terapêutica para cancros que expressam o antigénio cd40 |
EP1718670B1 (en) * | 2004-02-27 | 2011-07-13 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Il-15 binding site for il 15-ralpha and specific il-15 mutants having agonist/antagonist activity |
US20060234205A1 (en) * | 2004-03-05 | 2006-10-19 | Chiron Corporation | In vitro test system for predicting patient tolerability of therapeutic agents |
WO2009061853A2 (en) * | 2007-11-05 | 2009-05-14 | Massachusetts Institute Of Technology | Mutant interleukin-2 (il-2) polypeptides |
CN101244261B (zh) * | 2008-03-10 | 2010-09-15 | 山东大学 | 一种含未复性重组蛋白的生物制剂及其制备方法与应用 |
DE102008023820A1 (de) | 2008-05-08 | 2009-11-12 | Aicuris Gmbh & Co. Kg | Mittel zur Behandlung und/oder Prophylaxe einer Autoimmunerkrankung und zur Bildung von Regulatorischen T-Zellen |
WO2010085495A1 (en) | 2009-01-21 | 2010-07-29 | Amgen Inc. | Compositions and methods of treating inflammatory and autoimmune diseases |
CN102101885B (zh) * | 2010-09-01 | 2013-06-05 | 南京发士达生物科技有限公司 | 低诱导抑制性t细胞的人白细胞介素ⅱ突变体及其用途 |
HUE054318T2 (hu) | 2010-11-12 | 2021-08-30 | Nektar Therapeutics | IL-2 molekularész konjugátumai és polimer |
CU23923B1 (es) * | 2010-11-12 | 2013-07-31 | Ct De Inmunología Molecular | Polipéptidos derivados de la il-2 con actividad agonista |
WO2012088446A1 (en) | 2010-12-22 | 2012-06-28 | Board Of Trustees Of The Leland Stanford Junior University | Superagonists and antagonists of interleukin-2 |
EP3075745B1 (en) | 2011-02-10 | 2018-09-05 | Roche Glycart AG | Mutant interleukin-2 polypeptides |
WO2012119093A1 (en) * | 2011-03-03 | 2012-09-07 | Board Of Trustees Of The Leland Stanford Junior University | Superagonists and antagonists of interleukin-2 |
EA201892619A1 (ru) | 2011-04-29 | 2019-04-30 | Роше Гликарт Аг | Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2 |
US20140044675A1 (en) | 2012-08-10 | 2014-02-13 | Roche Glycart Ag | Interleukin-2 fusion proteins and uses thereof |
EP3049445A4 (en) | 2013-09-24 | 2017-10-25 | Medicenna Therapeutics, Inc. | Interleukin-2 fusion proteins and uses thereof |
PT3102595T (pt) | 2014-02-06 | 2019-01-11 | Hoffmann La Roche | Proteínas de fusão de interleucina-2 e suas utilizações |
GB201403775D0 (en) | 2014-03-04 | 2014-04-16 | Kymab Ltd | Antibodies, uses & methods |
WO2015164815A1 (en) | 2014-04-24 | 2015-10-29 | The Board Of Trustees Of The Leland Stanford Junior University | Superagonists, partial agonists and antagonists of interleukin-2 |
WO2016025385A1 (en) | 2014-08-11 | 2016-02-18 | Delinia, Inc. | Modified il-2 variants that selectively activate regulatory t cells for the treatment of autoimmune diseases |
US20170204154A1 (en) | 2016-01-20 | 2017-07-20 | Delinia, Inc. | Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases |
US20200316118A1 (en) * | 2016-05-19 | 2020-10-08 | The General Hospital Corporation | Tethered interleukin-2 to its receptor il-2rbeta, a platform to enhance natural killer and regulatory t cell activity |
KR102379464B1 (ko) | 2016-06-20 | 2022-03-29 | 키맵 리미티드 | 항-pd-l1 항체 |
US9567399B1 (en) | 2016-06-20 | 2017-02-14 | Kymab Limited | Antibodies and immunocytokines |
EP3475413B1 (en) * | 2016-06-22 | 2024-02-14 | David Klatzmann | Genetically modified t lymphocytes |
EP3534947A1 (en) | 2016-11-03 | 2019-09-11 | Kymab Limited | Antibodies, combinations comprising antibodies, biomarkers, uses & methods |
US11077172B2 (en) | 2016-11-08 | 2021-08-03 | Delinia, Inc. | IL-2 variants for the treatment of psoriasis |
CA3044416A1 (en) * | 2016-12-13 | 2018-06-21 | Delinia, Inc. | Multivalent regulatory t cell modulators |
CA3056630A1 (en) | 2017-03-15 | 2018-09-20 | Pandion Therapeutics, Inc. | Targeted immunotolerance |
JOP20190271A1 (ar) | 2017-05-24 | 2019-11-21 | Novartis Ag | بروتينات مطعّمة بسيتوكين- الجسم المضاد وطرق الاستخدام للاضطرابات المتعلقة بالمناعة |
EP3630162A1 (en) * | 2017-05-24 | 2020-04-08 | Novartis AG | Antibody-cytokine engrafted proteins and methods of use |
EP3630813A1 (en) | 2017-05-24 | 2020-04-08 | Novartis AG | Antibody-cytokine engrafted proteins and methods of use in the treatment of cancer |
CN111010866A (zh) | 2017-05-24 | 2020-04-14 | 潘迪恩治疗公司 | 靶向免疫耐受性 |
EP3641814A4 (en) | 2017-06-19 | 2021-06-23 | Medicenna Therapeutics Inc. | USES AND METHODS FOR IL-2 SUPERAGONISTS, AGONISTS, AND FUSIONS THEREOF |
AU2018309166B2 (en) * | 2017-08-03 | 2022-12-08 | Synthorx, Inc. | Cytokine conjugates for the treatment of proliferative and infectious diseases |
KR20200086722A (ko) * | 2017-11-21 | 2020-07-17 | 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 | 인터루킨-2의 부분 효능제 |
US10946068B2 (en) | 2017-12-06 | 2021-03-16 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
US10174091B1 (en) | 2017-12-06 | 2019-01-08 | Pandion Therapeutics, Inc. | IL-2 muteins |
AU2018390418B2 (en) | 2017-12-19 | 2023-12-21 | Xencor, Inc. | Engineered IL-2 Fc fusion proteins |
WO2019158764A1 (en) | 2018-02-16 | 2019-08-22 | Iltoo Pharma | Use of interleukin 2 for treating sjögren's syndrome |
EP3774861A1 (en) | 2018-03-28 | 2021-02-17 | Bristol-Myers Squibb Company | Interleukin-2/interleukin-2 receptor alpha fusion proteins and methods of use |
KR20200139730A (ko) | 2018-03-28 | 2020-12-14 | 아센디스 파마 온콜로지 디비전 에이/에스 | Il-2 접합체 |
WO2020007937A1 (en) | 2018-07-03 | 2020-01-09 | Iltoo Pharma | Use of interleukin-2 for treating systemic sclerosis |
WO2020020783A1 (en) * | 2018-07-24 | 2020-01-30 | Biontech Rna Pharmaceuticals Gmbh | Il2 agonists |
EP3836954A1 (en) | 2018-08-13 | 2021-06-23 | Iltoo Pharma | Combination of interleukin-2 with an interleukin 1 inhibitor, conjugates and therapeutic uses thereof |
EP3715367B1 (en) * | 2018-09-17 | 2024-06-12 | GI Innovation, Inc. | Fusion protein comprising il-2 protein and cd80 protein, and use thereof |
TW202034945A (zh) | 2018-12-21 | 2020-10-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | 一種人白細胞介素2變體或其衍生物 |
AU2020279240A1 (en) | 2019-05-20 | 2021-12-23 | Pandion Operations, Inc. | MAdCAM targeted immunotolerance |
TW202115105A (zh) * | 2019-06-24 | 2021-04-16 | 德商拜恩迪克Rna製藥有限公司 | Il2激動劑 |
JP2022544236A (ja) * | 2019-08-13 | 2022-10-17 | アムジエン・インコーポレーテツド | 制御性t細胞の増殖のためのインターロイキン-2変異タンパク質 |
JP2023505590A (ja) | 2019-12-12 | 2023-02-09 | イルトゥー・ファルマ | インターロイキン2キメラ構築物 |
CA3162705A1 (en) | 2019-12-17 | 2021-06-24 | Amgen Inc. | Dual interleukin-2 /tnf receptor agonist for use in therapy |
JP2023514010A (ja) | 2020-01-10 | 2023-04-05 | ブライト ピーク セラピューティクス エージー | 修飾il-2ポリペプチドおよびその使用 |
AU2021207652B2 (en) | 2020-01-14 | 2023-08-03 | Synthekine, Inc. | Biased IL2 muteins methods and compositions |
US11981715B2 (en) | 2020-02-21 | 2024-05-14 | Pandion Operations, Inc. | Tissue targeted immunotolerance with a CD39 effector |
EP4122952A4 (en) | 2020-03-19 | 2024-05-29 | Innovent Biologics (Singapore) Pte. Ltd. | INTERLEUKIN-2 MUTANT AND ITS USE |
US11746137B2 (en) | 2020-03-31 | 2023-09-05 | Hanmi Pharm. Co., Ltd. | Immunostimulating IL-2 analogs |
TW202210502A (zh) | 2020-06-03 | 2022-03-16 | 丹麥商阿森迪斯腫瘤製藥有限公司 | 新穎il-2序列及其用途 |
WO2022094275A1 (en) | 2020-10-29 | 2022-05-05 | Bristol-Myers Squibb Company | Fusion proteins for the treatment of disease |
CN114507643A (zh) * | 2020-10-29 | 2022-05-17 | 未来智人再生医学研究院(广州)有限公司 | 一种表达il-2的多能干细胞衍生物及应用 |
CN113308477A (zh) * | 2021-04-08 | 2021-08-27 | 华南农业大学 | 一种鸭il-2基因真核表达重组质粒及其制备方法 |
IL311643A (en) | 2021-09-22 | 2024-05-01 | Fortvita Biologics Singapore Pte Ltd | Interleukin-2 mutant and fusion protein |
WO2023057588A1 (en) | 2021-10-06 | 2023-04-13 | Iltoo Pharma | Interleukin 2 chimeric constructs with targeting specificy to inflamed tissues |
CN114875069B (zh) * | 2022-04-22 | 2023-09-15 | 四川大学 | 基因工程修饰的il2细胞因子的重组载体、宿主细胞及其用途 |
WO2023245097A2 (en) * | 2022-06-16 | 2023-12-21 | Cephalon Llc | Anti-pd-1 antibody-attenuated il-2 immunoconjugates and uses thereof |
WO2024056154A1 (en) | 2022-09-12 | 2024-03-21 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Interleukin-2 for use in treating autism spectrum disorder |
FR3140287A1 (fr) | 2022-10-03 | 2024-04-05 | Arkema France | Procede de granulation de composes azoiques et granules obtenus |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5696234A (en) * | 1994-08-01 | 1997-12-09 | Schering Corporation | Muteins of mammalian cytokine interleukin-13 |
-
1999
- 1999-05-12 DZ DZ990088A patent/DZ2788A1/xx active
- 1999-05-13 BR BRPI9910504A patent/BRPI9910504B1/pt not_active IP Right Cessation
- 1999-05-13 JP JP2000549735A patent/JP4276783B2/ja not_active Expired - Lifetime
- 1999-05-13 PL PL344407A patent/PL201675B1/pl unknown
- 1999-05-13 ES ES99924232T patent/ES2281175T3/es not_active Expired - Lifetime
- 1999-05-13 WO PCT/US1999/010643 patent/WO1999060128A1/en active IP Right Grant
- 1999-05-13 EP EP99924232A patent/EP1076704B1/en not_active Expired - Lifetime
- 1999-05-13 PE PE1999000399A patent/PE20000475A1/es not_active Application Discontinuation
- 1999-05-13 IL IL13913699A patent/IL139136A0/xx unknown
- 1999-05-13 HU HU0101948A patent/HU226142B1/hu unknown
- 1999-05-13 PA PA19998472601A patent/PA8472601A1/es unknown
- 1999-05-13 AT AT99924232T patent/ATE351907T1/de active
- 1999-05-13 TN TNTNSN99090A patent/TNSN99090A1/fr unknown
- 1999-05-13 PT PT99924232T patent/PT1076704E/pt unknown
- 1999-05-13 KR KR1020007012747A patent/KR100607609B1/ko not_active IP Right Cessation
- 1999-05-13 CN CNB998086509A patent/CN100366742C/zh not_active Expired - Lifetime
- 1999-05-13 SK SK1724-2000A patent/SK288100B6/sk not_active IP Right Cessation
- 1999-05-13 RU RU2000131593/04A patent/RU2235729C2/ru active
- 1999-05-13 DK DK99924232T patent/DK1076704T3/da active
- 1999-05-13 RO ROA200001123A patent/RO122150B1/ro unknown
- 1999-05-13 SI SI9920034A patent/SI20643B/sl active Search and Examination
- 1999-05-13 TR TR2000/03354T patent/TR200003354T2/xx unknown
- 1999-05-13 NZ NZ508098A patent/NZ508098A/en not_active IP Right Cessation
- 1999-05-13 UA UA2000127206A patent/UA73719C2/uk unknown
- 1999-05-13 DE DE69934881T patent/DE69934881T2/de not_active Expired - Lifetime
- 1999-05-13 CA CA2327349A patent/CA2327349C/en not_active Expired - Lifetime
- 1999-05-13 CN CN2007101609093A patent/CN101319247B/zh not_active Expired - Lifetime
- 1999-05-13 CZ CZ20004213A patent/CZ302071B6/cs not_active IP Right Cessation
- 1999-05-13 AU AU40784/99A patent/AU759697B2/en not_active Expired
- 1999-05-13 AR ARP990102269A patent/AR020322A1/es active IP Right Grant
- 1999-05-14 MY MYPI99001912A patent/MY130274A/en unknown
- 1999-05-14 HN HN1999000075A patent/HN1999000075A/es unknown
- 1999-05-14 TW TW088107812A patent/TWI223663B/zh not_active IP Right Cessation
- 1999-05-14 SV SV1999000061A patent/SV1999000061A/es active IP Right Grant
- 1999-05-14 CO CO99030158A patent/CO5070701A1/es unknown
-
2000
- 2000-10-18 IL IL139136A patent/IL139136A/en not_active IP Right Cessation
- 2000-11-08 BG BG104929A patent/BG65139B1/bg unknown
- 2000-11-14 NO NO20005762A patent/NO329235B1/no not_active IP Right Cessation
- 2000-11-15 CU CU20000257A patent/CU23273B7/es not_active IP Right Cessation
-
2002
- 2002-02-21 HK HK02101283.2A patent/HK1039963B/zh not_active IP Right Cessation
- 2002-06-19 CU CU20020125A patent/CU23272A1/es not_active IP Right Cessation
-
2007
- 2007-03-09 CY CY20071100330T patent/CY1107533T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PA8472601A1 (es) | Agonistas y antagonistas il-2 selectivos | |
AR036711A1 (es) | Peptidos que actuan como agonistas del receptor del glp-1 y como antagonistas del receptor del glucagon y sus metodos de uso farmacologico | |
GT199700095A (es) | Derivados 6,5-heterobiciclicos sustituidos. | |
ES2171768T3 (es) | Inhibidores de la resorcion osea y antagonistas de receptores de vitronectina. | |
MX9303554A (es) | Peptido similar al glucagon y derivados de insulinotropina. | |
AR046877A1 (es) | Muteinas del factor de crecimiento de fibroblastos 21 | |
ATE33503T1 (de) | Pharmazeutische und tiermedizinische praeparate von interleukin-2, in dem cystein-125 ausgetauscht worden ist (muteine), sowie deren herstellung. | |
UY27721A1 (es) | Anticuerpos humanizados que reconocen el peptido amiloide beta. | |
ES2185816T3 (es) | Formas de dosificacion farmaceutica para la via oral, que comprenden un agente inhibidor de la bomba de protones y un agente procinetico. | |
DE59202585D1 (de) | Mittel mit physiologischem Kühleffekt und für diese Mittel geeignete wirksame Verbindungen. | |
PA8461701A1 (es) | Derivados de 9-amino-3-ceto eritromicina | |
GT199800083A (es) | Agonistas de prostaglandinas. | |
ES2125567T3 (es) | Uso de un antagonista de serotonina en combinacion con un antagonista del receptor de taquiquinina para la fabricacion de un medicamento para la prevencion o el tratamiento de la migraña. | |
AR002949A1 (es) | Análogos del peptido p277 y composiciónes farmaceuticas y preparaciónes que los comprenden para el tratamiento o diagnostico de diabetes y un equipo para diagnosticar. | |
EE200100478A (et) | Vahend artriitilise haiguse raviks | |
BR9916190A (pt) | Emprego de inibidores do canal kqt1 para a preparação de um medicamento para o tratamento de doenças, que são provocadas por helmintos e ectoparasitas | |
MX9307991A (es) | Analogos de insulina, procedimiento para su preparacion y formulaciones farmaceuticas que los incluyen. | |
ES2039040T3 (es) | Paramentos para movimientos de tierra. | |
CO2021017639A2 (es) | Agonistas de il2 | |
ES2172703T3 (es) | Composiciones de fluoruro de perfluoro(alcoxiciclo alcano)carbonilo, y su uso. | |
ES2129893T3 (es) | Dinucleosido-5',5'-pirofosfatos. | |
ECSP992953A (es) | Agonistas y antagonistas il-2 selectivos (caso 5038p1-ec) | |
ES2016781A4 (es) | Procedimiento para regulacion del cloro libre residual en el agua. | |
ES2183007T3 (es) | Empleo de muteinas de citoquinas de tipo salvaje como inmunogenos. | |
ES2061908T3 (es) | Antagonistas competitivos de gonadoliberina. |